Close

JPMorgan Assumes Mirati Therapeutics (MRTX) at Overweight

August 1, 2022 4:42 PM EDT Send to a Friend
JPMorgan analyst Eric Joseph assumes coverage on Mirati Therapeutics (NASDAQ: MRTX) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login